Ascendis Pharma A/S (ASND)

Market Cap	7.75B
Revenue (ttm)	296.35M
Net Income (ttm)	-534.94M
Shares Out	56.61M
EPS (ttm)	-9.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	364,688
Open	140.01
Previous Close	143.18
Day's Range	136.19 - 140.84
52-Week Range	66.03 - 161.00
Beta	0.51
Analysts	Buy
Price Target	170.25 (+24.33%)
Earnings Date	May 2, 2024

About ASND

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 28, 2015
• Employees: 879
• Stock Exchange: NASDAQ
• Ticker Symbol: ASND

Financial Performance

In 2023, ASND's revenue was 266.72 million, an increase of 421.20% compared to the previous year's 51.17 million. Losses were -481.45 million, -17.45% less than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 8 analysts, the average rating for ASND stock is "Buy." The 12-month stock price forecast is $170.25, which is an increase of 24.33% from the latest price.

Price Target

$170.25

(24.33% upside)

Analyst Consensus: Buy